In this study we 
INTRODUCTION
The physiological entry of iron into cells is dependent upon the presence of specific cell surface receptors for the plasma iron-transport protein transferrin (Jandl & Katz, 1963) . Following binding, the receptor-ligand complex is endocytosed (Morgan & Appleton, 1969; Karin & Mintz, 1981) and the iron released from the two ironbinding sites of the protein (Ciechanover et al., 1983; Bomford et al., 1985) . This is achieved through a process of reduction and/or protonation in the intravesicular acid environment (van Renswoude et al., 1982) thought to be generated by an ATP-Mg2+-dependent mechanism (Yamashiro et al., 1983) . The point in the cycle at which iron is released from the endosome is unknown, but in view of the toxic nature of free iron (Halliwell & Gutteridge, 1984) it is unlikely that it remains, at any time, in an uncomplexed form. Implicit in the proposed mechanisms of iron release from transferrin is the need for an acceptor molecule (Aisen & Listowsky, 1980) . Presumably such species are required both within the endosome and across its membrane barrier in the cytosol.
The concept of a cytosolic chelatable iron pool into which transferrin iron is fed en route to functional haemcontaining enzymes or the storage compound ferritin has been inferred (Jacobs, 1977) from experiments in which low-molecular-mass iron has been identified in a number of cell types (Lipschitz et al., 1971; White et al., 1976a; Octave et al., 1983) . These studies have used the permeant iron-chelating agent desferrioxamine in an attempt to define the intracellular sources of iron available for chelation. However, the specific relationship between chelatable iron and the dynamics of the transferrin cycle have not been investigated.
In the present study we have examined the kinetics of desferrioxamine uptake into K562 cells by determining the extracellular concentration of chelator and duration of exposure required to achieve maximum binding of iron entering the cell on transferrin. In additional experiments the compound was used as a competitive acceptor molecule for iron liberated during the transferrin cycle to characterize the kinetics of iron release from the endosome and the partition of iron between transferrin, chelatable and ferritin pools. The inclusion of a lysosomotropic agent which prevents acidification of the endosome and iron release from transferrin has allowed us to determine whether desferrioxamine has direct access to iron while it remains coupled to the protein. EXPERIMENTAL (Bomford et al., 1986a) . Cultures were maintained in exponential-phase growth at densities of (2-7) x 105 cells/ml.
Preparation of 59Fe-labelled transferrin
Transferrin was prepared from pooled and ironsaturated human plasma as previously described (Bomford et al., 1983) using DEAE-Sepharose chromatography to yield diferric transferrin with an A470/A410 ratio greater than 1.3. Apotransferrin was prepared by repeated citrate dialysis (Young et al., 1984) and made diferric with 59Fe (Bomford et al., 1983) . Non-specifically bound iron was removed by chromatography on the anion-exchange resin Dowex I-X8 (Cavill, 1971) .
Uptake of desferrioxamine and partition of 59Fe between desferrioxamine and ferritin in K562 cells 59Fe-labelled human diferric transferrin was used as the source of iron for intracellular chelation by desferrioxamine. Cells were spun down and resuspended twice at 37°C for 15 min in incubation medium to free receptors of endogenous bovine transferrin and then incubated at 37°C for 1 or 4 h with various concentrations (20 /SM-5 mM) of freshly prepared desferrioxamine in 10 ml of RPMI containing 1 % BSA (incubation medium). They were then incubated at 37°C for 3 h with 310 nM- Detection of ferrioxamine by column chromatography Cell lysates and re-incubation media were applied to a column of Sephadex G-50 (10 mm x 200 mm) equilibrated and eluted with 25 mM-Hepes, pH 7.4, 130 mMNaCl and 1 ml fractions were collected and counted in a Compugamma counter (LKB). A standard [59Fe]-ferrioxamine preparation was found to be eluted in fractions 21-33 and counts from samples corresponding to a peak within these fractions were taken to be [59Fe]ferrioxamine.
Immunoprecipitation of 159Felferritin
An antiserum to purified human liver ferritin (Bomford et al., 1977) was raised in rabbits using an immunization schedule previously described (Bomford et al., 1981) . The antiserum was specific for human liver ferritin as shown by radial immunodiffusion and immunoelectrophoresis. Ferritin was isolated from cell lysates using direct immunoprecipitation. Purified human liver ferritin (20 4tg) was added to 0.5 ml of cell lysate followed by 30,tl of specific antiserum and incubated for 1 h at 37 'C. The tubes were then incubated overnight at 4 'C and the brown precipitate was recovered by centrifugation at 12000 ga, for O min. The pellets were washed four times in lysis buffer at 4 'C and counted in a gamma counter. The specificity of these conditions for precipitating ferritin was validated according to Bomford et al. (1986b) .
RESULTS

Assessment of desferrioxamine uptake by K562 cells
Iron entering the cells on transferrin was found to be readily accessible to intracellular chelator since [59Fe]-ferrioxamine was rapidly generated when cells preloaded with desferrioxamine for 1-4 h were incubated with [59Fe]transferrin (see below). To investigate the kinetics of entry of desferrioxamine, cells were incubated with chelator at 37 'C and pulsed at intervals with
[59Fe]transferrin. The percentage of iron partitioning to ferrioxamine as assessed by both benzyl alcohol extraction and column chromatography increased over a 40-60 min period but thereafter remained constant (Fig. 1) . When the extracellular concentration was 100 1tM an equilibrium was achieved where approx. 20 % of the 10 min pulse was converted to ferrioxamine. The steady level of ferrioxamine was raised to 50 % at an extracellular concentration of 500 ,UM while the profiles of formation of [59Fe]ferrioxamine at the two concentrations were similar. These results show that the extracellular desferrioxamine concentration is important in determining the percentage of a pulse of transferrin iron that is bound by the chelator, while prolonged exposure to the drug does not lead to a greater percentage generation of ferrioxamine. There is, therefore, rapid uptake of desferrioxamine by K562 cells with equilibrium being reached by 40-60 min for both concentrations used.
Partition of intracellular 59Fe to ferrioxamine
To characterize further the partitioning of transferrin iron to ferrioxamine, cells were pre-exposed to various concentrations of desferrioxamine (20 uM-5 mM) for 1 and 4 h and the formation of [59Fe]ferrioxamine was assessed during a subsequent 3 h incubation with [59Fe]transferrin. The percentage of the iron that became bound to desferrioxamine was wholly dependent upon the extracellular chelator concentration and not the length of the preincubation (Fig. 2) . There was extensive (80-90 %O) conversion of 59Fe to ferrioxamine in the presence of 1-S mM-desferrioxamine, whereas at lower concentrations there was a decreased partitioning of the iron to chelator so that at an extracellular concentration of 20 /tM only 100 of the iron entering the cell on transferrin was chelated. Binding of 75 00 of entering iron occurred over a 10 min period when cells were pre-incubated with 5 mM-desferrioxamine. Since, under these conditions, desferrioxamine was in excess (Fig. 2) There was a linear increase in the total amount of Partition of intracellular 59Fe to ferritin In the presence of low concentrations of desferrioxamine (20-500 gLM) a proportion (Fig. 2) of the iron delivered to the cells remained unbound by chelator. To determine whether this residual iron followed its anticipated route to the iron storage protein ferritin (Mattia et al., 1986) , [59Fe]ferritin levels were measured in duplicate samples taken at the 3 h time point (Fig. 2) . In control cells approx. 50 % of the 59Fe was incorporated into immunoprecipitable ferritin (Fig. 4) . In the presence of increasing extracellular concentrations of desferrioxamine there was a decrease in the proportion of the counts found in ferritin with less than 5 % of the iron following this pathway when the concentration was in (Fig. 5) with 5000 of the total loss occurring within 1.5-2 h. As the concentration gradient between intra-and extra-cellular ferrioxamine neared equilibrium, which was reached at around 24 h (results not shown), the rate of release slowed.
Chelation of transferrin iron during endocytosis
To examine whether iron was directly available to the chelator throughout the endocytic cycle or whether uncoupling from the protein was first required, cells were preincubated with the weak base methylamine, which prevents the release of iron from the two iron-binding sites of transferrin in K562 cells (Bomford et al., 1985) . Cells were loaded with 1 mM-desferrioxamine, preincubated with 5 mM-methylamine and the uptake of iron from [59Fe]transferrin was measured over 3 h. Methylamine markedly reduced iron uptake by both the desferrioxamine-treated and control cells (Fig. 6 ) whereas in the absence of the base there was a linear uptake of iron. The formation of [59Fe]ferrioxamine in cell lysates from the 3 h time point was inhibited by approx. 800 by methylamine (Fig. 7) . Although, at this concentration of methylamine, cycling of the transferrin receptor in K562 cells is slowed to some extent (Bomford et al., 1985; Ciechanover et al., 1983) , at least eight to ten rounds of endocytosis would be completed during the experimental period used here and it was concluded that uncoupling of iron from endocytosed transferrin was a prerequisite before this iron was in a chelatable form.
DISCUSSION
The majority of intracellular iron resides in proteinbound forms and two of these, transferrin and ferritin, have been extensively studied and well characterized.
However, there appears to be a further biochemically indistinct pool of low-molecular-mass iron (Jacobs, 1977; Pollack & Campana, 1980) variously termed chelatable or labile (Jacobs, 1977) . The concept has arisen that this pool is in equilibrium with iron donated to the cell by the transferrin cycle, with storage iron, in the form of ferritin, and with iron-dependent enzymes, some of which may have an important regulatory role in cellular iron metabolism. The functional significance of this pool would seem to be in a feed-back capacity by regulating the proteins that mediate the uptake (Testa et al., 1985) and storage of iron (Rittling & Woodworth, 1984) . When cells in culture are exposed to micromolar concentrations of desferrioxamine, leading to binding of iron within the pool, they respond by up-regulating transferrin receptors, an event which occurs after some hours (Bridges & Cudkowicz, 1984) and is probably under transcriptional control . Conversely, iron supplementation, in the form of haemin (Rouault et al., 1985) or diferric transferrin (Louache et al., 1984 ) is thought to result in an enrichment of this pool and leads to receptor down-regulation. The level of chelatable iron within the cell has an analogous role in the regulation of ferritin synthesis (Rogers & Munro, 1987) through redistribution of mRNAs for the two protein subunits between the free pool and that bound to polyribosomes.
The location at which desferrioxamine exerts its effect and the sources of iron available for chelation are poorly characterized. Previous studies using cultured hepatocytes (Octave et al.. 1983 ) and Chang cells (White et al., 1976b) have focused on ferritin as the major source of chelatable iron. Although in the intact animal model it has been demonstrated that 59Fe donated to hepatocytes by transferrin is effectively chelated (Pippard et al., 1982) the mechanisms involved were not investigated. In view of the abundant (Klausner et al., 1983) and closely regulated (Louache et al., 1984) numbers of transferrin receptors on K562 cultured erythroleukaemia cells it can be anticipated that the transferrin cycle could provide a dynamic and potentially rich source of iron for an intracellular chelating agent.
We initially investigated the rate at which desferrioxamine entered K562 cells using an indirect method in which the conversion of repeated pulses of [59Fe]-Vol. 254 transferrin to [59Fe]ferrioxamine was determined. Maximal conversion of the pulse occurred when the cells had been exposed to desferrioxamine for 40-60 min suggesting that by this time equilibrium had been reached. These results are in close accord with those of Laub et al. (1985) , who found that the uptake into cultured hepatocytes of derivatized forms of desferrioxamine reached a plateau after 60 min and that the total uptake was proportional to the extracellular concentration of the compound. These results contrast with the evidence of Bottomley et al. (1985) , who investigated directly the uptake of a "C-labelled preparation of the chelator in K562 cells. They found continued uptake of the label over a 24 h period, when cells were incubated in 20 /iM-["4C]desferrioxamine with a resultant 14-fold accumulation of 14C within the cell. We have also observed (S. Roberts & A. Bomford, unpublished results) linear uptake of [14C] desferrioxamine by K562 cells with a 6-20-fold accumulation of the label when extracellular concentrations of between 100 fLM and 1 mm were used. However, because of the evidence that there is extensive degradation of the drug in mammalian plasma and a degree of cellular metabolism by cultured hepatocytes (Laub et al., 1985) these results are difficult to interpret since intracellular 14C is not a true reflection of the level of intact and functioning desferrioxamine. This problem is avoided in the present study because we assessed the intracellular chelating capacity at a given extracellular concentration and did not attempt to determine the actual intracellular level of desferrioxamine.
At all concentrations of desferrioxamine, [59Fe]-ferrioxamine was rapidly generated, indicating that there was immediate chelation of transferrin-derived iron, although over the first 10 min of the incubation ligand-receptor cycling, iron release from transferrin and passage to the cytosol appeared to limit the initial rate of ferrioxamine formation. In the range 20-500 /tM the partitioning of iron to chelator was wholly dependent on the extracellular concentration of desferrioxamine, provided the cells had been preincubated with the drug for longer than 60 min. Given that the effective intracellular chelating capacity rose with increased extracellular concentration we propose that the proportion of iron bound is a reflection of the amount of desferrioxamine within the cell. The partitioning of iron to chelator may also be dependent upon the relative affinities of desferrioxamine and any endogenous ironacceptor molecule, which if it is to compete for ferric iron must have an affinity constant in the order of 1031. At concentrations greater than 1 mm when intracellular levels of chelator were in excess of iron delivery (which was dependent upon the rate of endocytosis), there was complete conversion of iron to ferrioxamine. This again contrasts with previous data from Bottomley et al. (1985) who reported that only 40 ,M-desferrioxamine led to 86 % [59Fe]ferrioxamine formation as assessed by coelution of cell lysate with a standard on a Sephadex G-50 column. It is difficult to understand the 20-fold discrepancy between their results and those of the present study. An explanation may lie in the 24 h preincubation of cells with chelator used by Bottomley et al. (1985) . This would cause increased iron delivery through upregulation oftransferrin receptors (Bridges & Cudkowicz, 1984; Mattia et al., 1984) and decreased iron storage capacity through a reduction in ferritin protein synthesis (Rittling & Woodworth, 1984) which may be sufficient to explain the increased partitioning of entering iron to chelator. Our results also indicate that an equilibrium exists between the entry of desferrioxamine into cells, the generation of the iron loaded form and the release of ferrioxamine from the cells since once maximum intracellular chelating concentrations have been reached there is no decline in the fraction of iron following this pathway.
If, however, intracellular desferrioxamine concentrations are insufficient to bind all the iron entering the cells the residual iron passes to the storage protein ferritin, so the possibility exists that after continued incubation, chelator may remove iron from this source. Our preliminary results (not shown) suggest that for up to 4 h after binding by ferritin, iron may be accessible to desferrioxamine. A recent report (Mattia et al., 1986) has indicated that iron liberated from transferrin can reside within the cell for 2-5 h before becoming incorporated into ferritin. We suggest that desferrioxamine interrupts the flow of iron into this pre-ferritin compartment and may bind iron directly while it remains loosely associated with the molecule.
The prolonged incubation ofcells with desferrioxamine affected the partition of iron between ferrioxamine and ferritin in an additional way. The translation of ferritin mRNA is sensitive through cytoplasmic control (Zahringer et al., 1976) to levels of chelatable iron within the cell (Rogers & Munro, 1987) so that changes in ferritin protein synthesis are effected in a matter of 4-6 h (Drysdale & Munro, 1966) . Mattia et al. (1986) have proposed that the regulation of intracellular iron distribution is dependent upon absolute ferritin levels and is unaffected over a wide range of concentrations of iron delivered to the cell. Our results lend support to this theory. Cells which were incubated with desferrioxamine for a total of 7 h had levels of intracellular chelator identical with those incubated for a total of 4 h (Fig. 2) , but the fraction of the total cellular iron partitioning to ferritin was reduced by between 30-35 % after the longer exposure (Fig. 4) which may correlate with the expected reduction in the level of ferritin protein.
We have also shown that desferrioxamine can only bind transferrin iron after it has been released from the endocytosed protein, suggesting that the chelator is competing with an endogenous acceptor molecule within either the endosome, the endosomal membrane or in the cytosol. Neutralization of intravesicular pH with methylamine which leads to the recycling of the diferric species (Bomford et al., 1985) prevented the release of iron to desferrioxamine and markedly reduced ferrioxamine formation. Whether desferrioxamine exerts its action within the endosome or at a cytosolic location is unclear. This chelating agent enters lysosomes (Laub et al., 1985) and possibly other types of intracellular vesicle, but since the transferrin-containing endosome has a residency time of only 5-10 min in K562 cells (Klausner et al., 1983; Bomford et al., 1985) it would seem unlikely that effective concentrations of the chelator could accumulate within the vesicle during this period. In addition the half-time for ferrioxamine release (1. 
